Skip to content
Search for:
About us
Overview
History
Management Board
Ethical management
Areas of Partnership
Location
Core Technology
NexP™ Fusion Technology
NexMab™ ADC Technology
Biosimilars
Technological Outcomes
Pipeline
Overview
Project
ALT-P1
ALT-Q2
Project
ALT-P7
ALT-Q5
Project
ALT-L9
ALT-L2
ALT-LS2
ESG
ESG introduction
ESG introduction
ESG Goal
ESG Guide line
Environmental
Environmental management
Safety and Health management
Introduction
Social
Charter
Counseling Center
Consultation Application
Board of directors
Board of directors
Audit System
Compliance Management
Ethics Charter
IR
News
Reports
Notices
Career
Whom Alteogen is Looking for
Job Notice
로그인
한국어
Loading...
News
alteogen
2018-04-27T13:47:37+09:00
News
Reports
Notices
News
Number
Title
Author
Date
Notice
Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products
alteogen
|
2023.01.06
|
Votes 0
|
Views 1255
alteogen
2023.01.06
Notice
Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients
alteogen
|
2023.01.06
|
Votes 0
|
Views 728
alteogen
2023.01.06
Notice
Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products
alteogen
|
2023.01.06
|
Votes 0
|
Views 711
alteogen
2023.01.06
Notice
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme™ Technology
alteogen
|
2023.01.06
|
Votes 0
|
Views 799
alteogen
2023.01.06
Notice
Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of Its Hybrozyme™Technology
alteogen
|
2023.01.06
|
Votes 0
|
Views 538
alteogen
2023.01.06
29
Merck to Manufacture Next-Generation Biotherapeutics for Alteogen
alteogen
|
2023.01.06
|
Votes 0
|
Views 651
alteogen
2023.01.06
28
Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020
alteogen
|
2023.01.06
|
Votes 0
|
Views 435
alteogen
2023.01.06
27
Alteogen Inc. obtained IND approval for a clinical trial in Korea for Eylea Biosimilar (ALT-L9)
alteogen
|
2019.05.22
|
Votes 0
|
Views 3787
alteogen
2019.05.22
26
Alteogen applies for P1 trial for Eylea biosimilar
alteogen
|
2019.02.28
|
Votes 0
|
Views 2438
alteogen
2019.02.28
25
Alteogen Inc. Becomes First Mover for Eylea Biosimilar with securing global competitiveness by registering patent
alteogen
|
2019.01.04
|
Votes 0
|
Views 2623
alteogen
2019.01.04
24
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH
alteogen
|
2018.12.04
|
Votes 0
|
Views 2504
alteogen
2018.12.04
23
Alteogen's Kadcyla biobetter gains edge in gastric cancer with FDA orphan designation
alteogen
|
2018.08.17
|
Votes 0
|
Views 2299
alteogen
2018.08.17
22
Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer
alteogen
|
2018.08.07
|
Votes 0
|
Views 2101
alteogen
2018.08.07
21
Alteogen develops antibody transferring IV to SC injection
alteogen
|
2018.07.30
|
Votes 0
|
Views 1827
alteogen
2018.07.30
20
Alteogen, Lynkogen targeting large NASH, diabetes markets in cross-royalty collaboration
alteogen
|
2018.07.11
|
Votes 0
|
Views 1840
alteogen
2018.07.11
1
2
3
»
Last
All
Title
Content
Author
Search
Go to Top